arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024 16:42 ET | Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...
Celcuity+Logo.jpg
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
May 08, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
May 08, 2024 07:02 ET | Olema Oncology
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
arvinas_logoART_lg.jpg
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:00 ET | Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
biomerica.png
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
April 29, 2024 08:19 ET | Biomerica, Inc.
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning...
Current paradigm of HER2 expression scoring
Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination
April 25, 2024 08:00 ET | SDS Optic S.A.
SDS Optic's positive results from the Part I Clinical Trial of the novel optic fiber probe, inPROBE®, in vivo real-time molecular diagnostic technology.
arvinas_logoART_lg.jpg
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Logo.jpg
Breast Cancer Market To Reach USD 4.3 Billion By 2032, Says DataHorizzon Research
April 23, 2024 05:40 ET | DataHorizzon Research
Fort Collins, Colorado, April 23, 2024 (GLOBE NEWSWIRE) -- The growing prevalence of breast cancer drives the need for diagnostics in the forecast period. The prevalence of breast cancer...
22157.jpg
Global Portable Ultrasound Market Analysis Report 2024-2031: Use of Artificial Intelligence in Portable Ultrasound Devices and Emergence of Wearable Ultrasound Devices Gaining Momentum
April 18, 2024 07:23 ET | Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Portable Ultrasound Market by Product (POCUS, Handheld Ultrasound, Transducer, Gels), Technology (2D, 3D, 4D, Doppler), Display, Application (Breast...